New York’s attorney general has been investigating 16 major health insurers and whether they limit or ration coverage for effective expensive recent drugs for treating Hepatitis C.
The investigation of two insurers began last fall and has recently expanded to include the others. Subpoenas have been issued.
Insurers have sought discounts from pharmaceutical company Gilead from the prices of $94,000 for Harvoni and $83,000 for Sovaldi per course of treatment.
Worldwide, an estimated 185 million people are infected with the liver-destroying virus.
Empire Blue Cross Blue Shield, which covers four million New Yorkers, says it expanded coverage as of Dec. 7 to include patients in all stages of liver fibrosis after clinical reviews for six newer oral medications, including those two.